INDIANAPOLIS, – The EMPACT-MI phase III clinical trial showed a 10% relative risk reduction in the primary composite endpoint of time to first hospitalization due to heart failure or all-cause mortality for Jardiance® (empagliflozin) versus placebo, which did not reach statistical significance. Jardiance was initiated in adults within 14 days of an acute myocardial infarction, commonly known as a heart attack, and …
Washington – There are no shortcuts when developing safe and effective medicines. On average, it can take 10-15 years to bring a new medicine from early-stage research through clinical trials. The reality is, despite recent scientific advances, there are many serious and life-threatening diseases that lack meaningful treatments, therapies, or cures. Waiting a decade could be the difference between life …
Australia – A new study published in the British Journal of Psychiatry says more than one in five patients with treatment-resistant depression saw severe depression symptoms disappear after receiving ketamine injections in a clinical trial, while one third reported their symptoms improved by at least 50 per cent. Lead author Colleen Loo said in a news release: “We found that …
